5.86
price down icon7.57%   -0.48
after-market 시간 외 거래: 5.86
loading
전일 마감가:
$6.34
열려 있는:
$6.17
하루 거래량:
369.59K
Relative Volume:
1.78
시가총액:
$296.33M
수익:
-
순이익/손실:
$-76.41M
주가수익비율:
-3.0521
EPS:
-1.92
순현금흐름:
$-64.56M
1주 성능:
-16.29%
1개월 성능:
-21.76%
6개월 성능:
-34.23%
1년 성능:
-25.35%
1일 변동 폭
Value
$5.72
$6.455
1주일 범위
Value
$5.72
$7.25
52주 변동 폭
Value
$5.72
$12.38

Aura Biosciences Inc Stock (AURA) Company Profile

Name
명칭
Aura Biosciences Inc
Name
전화
(617)500-8864
Name
주소
80 GUEST STREET, BOSTON
Name
직원
106
Name
트위터
Name
다음 수익 날짜
2025-03-24
Name
최신 SEC 제출 서류
Name
AURA's Discussions on Twitter

AURA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
AURA
Aura Biosciences Inc
5.86 296.33M 0 -76.41M -64.56M -1.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-07-25 개시 H.C. Wainwright Buy
2023-07-27 개시 Scotiabank Sector Outperform
2023-04-17 재개 BTIG Research Buy
2022-07-19 개시 JMP Securities Mkt Outperform

Aura Biosciences Inc 주식(AURA)의 최신 뉴스

pulisher
12:32 PM

Aura Biosciences stock hits 52-week low at $5.75 amid market challenges - Investing.com

12:32 PM
pulisher
09:31 AM

Are Investors Keen On Selling Holdings In Aura Biosciences Inc (NASDAQ: AURA)? - stocksregister.com

09:31 AM
pulisher
Mar 28, 2025

Q1 Earnings Estimate for AURA Issued By HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Aura Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 20% drop adds to a year losses - Simply Wall St

Mar 27, 2025
pulisher
Mar 27, 2025

Aura Biosciences Inc: Promising Clinical Progress and Financial Stability Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

What is HC Wainwright’s Forecast for AURA Q3 Earnings? - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress - markets.businessinsider.com

Mar 27, 2025
pulisher
Mar 26, 2025

Aura Biosciences price target lowered to $19 from $21 at Citizens JMP - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Character Biosciences gains $93m for precision eye disease therapies - Pharmaceutical Technology

Mar 26, 2025
pulisher
Mar 26, 2025

Bel-sar shows promising safety, efficacy in NMIBC - Urology Times

Mar 26, 2025
pulisher
Mar 26, 2025

Aura Biosciences stock target cut to $19 by JMP Securities - Investing.com UK

Mar 26, 2025
pulisher
Mar 26, 2025

Aura Biosciences Reports Progress in Cancer Trials - TipRanks

Mar 26, 2025
pulisher
Mar 25, 2025

Aura Biosciences Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

Aura Biosciences stock target raised to $25 by H.C. Wainwright - Investing.com UK

Mar 25, 2025
pulisher
Mar 25, 2025

Promising Clinical Data and Abscopal Effect Drive Buy Rating for Aura Biosciences Inc. - TipRanks

Mar 25, 2025
pulisher
Mar 24, 2025

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Aura's Cancer Drug Delivers Complete Responses as $151M Cash Runway Extends to 2026 - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

Promising Phase 1 Results for Aura Biosciences’ Bel-sar in Bladder Cancer Boost Buy Rating - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura reports promising bladder cancer trial results By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences stock hits 52-week low at $6.58 amid market shifts - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Buy Recommendation for Aura Biosciences: Promising Phase 1 Trial Results and Dual Mechanism of Action in Bladder Cancer Treatment - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences stock hits 52-week low at $6.58 amid market shifts By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Buy Rating for Aura Biosciences Inc. Driven by Promising Phase 1 Trial Results and Future Revenue Potential - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences Reports 'Robust' Anti-Tumor Immune Response From Phase 1 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Aura reports promising bladder cancer trial results - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences announces data from Phase 1 trial of bel-sar in NMIBC - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Positive Data from Phase 1 Trial of Bel-sar in Patients - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Breakthrough: New Bladder Cancer Drug Achieves 80% Response Rate in Clinical Trial - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

With 48% stake, Aura Biosciences, Inc. (NASDAQ:AURA) seems to have captured institutional investors' interest - Yahoo Finance

Mar 24, 2025
pulisher
Mar 21, 2025

Aura Biosciences, Inc. (NASDAQ:AURA) Sees Large Decrease in Short Interest - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Analysts Set Groupon, Inc. (NASDAQ:GRPN) PT at $17.33 - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Innovative Industrial Properties, Inc. (NYSE:IIPR) Receives $102.00 Average Target Price from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus Target Price from Brokerages - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Learn to Evaluate (AURA) using the Charts - news.stocktradersdaily.com

Mar 19, 2025
pulisher
Mar 19, 2025

Aura Biosciences (AURA) to Release Quarterly Earnings on Wednesday - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7% - MSN

Mar 16, 2025
pulisher
Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire

Mar 06, 2025
pulisher
Mar 05, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) & Aura Biosciences (NASDAQ:AURA) Critical Survey - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

H.C. Wainwright maintains $22 target on Aura Biosciences stock By Investing.com - Investing.com UK

Mar 04, 2025
pulisher
Mar 03, 2025

Buy Rating for Aura Biosciences Driven by Promising Bel-sar Developments and Market Potential - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Promising Developments in Aura Biosciences Inc’s Clinical Trials Lead to Buy Rating - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Aura Biosciences to present new bladder cancer study data - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Aura Biosciences to Present Phase 1 Data on Bel-sar and Host Virtual Urologic Oncology Investor Event at 40th Annual EAU Congress - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Will Aura's Bladder Cancer Treatment Change Patient Outcomes? New Data Coming in 2025 - StockTitan

Mar 03, 2025
pulisher
Feb 25, 2025

How to Take Advantage of moves in (AURA) - news.stocktradersdaily.com

Feb 25, 2025
pulisher
Feb 25, 2025

Syndax Announces Participation in March Investor Conferences - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

How Will Aura Biosciences Address Investors at Two Major Healthcare Conferences Next Month? - StockTitan

Feb 25, 2025
pulisher
Feb 24, 2025

Advancing Immunotherapy With FDA Approval Of ANKTIVA For BCG-Unresponsive Bladder Cancer: Key Trend Transfo... - WhaTech

Feb 24, 2025

Aura Biosciences Inc (AURA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
자본화:     |  볼륨(24시간):